Critically ill patients with cancer: A clinical perspective

doi:10.5306/wjco.v11.i10.809

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8736)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-10) series.

Item

Count

PDF

588

WORD

268

HTML

4337

Figures (1-4)

300

Tables (1-10)

333

Sum=5826

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

372

Download

654

Sum=1026

Publishing Process of This Article

Item

Count

Browse

688

Download

1196

Sum=1884

Oct 24, 2020 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Oct 24, 2020; 11(10): 809-835
Published online Oct 24, 2020. doi: 10.5306/wjco.v11.i10.809

Table 7 Empiric antibiotic therapy in high-risk patients with febrile neutropenia[40,54,55,79,83]

Antibiotherapy	Indication
Antipseudomonal β-lactam agent (cefepime, ceftazidime)	All patients with febrile neutropenia
OR
Carbapenem (meropenem or mipenem/cilastatin)	Hemodynamic instability
OR
Piperacillin/tazobactam
OR
Novel cephalosporin/β-lactamase inhibitor (Ceftolozane/tazobactam or Ceftazidime/avibactam)
PLUS
Aminoglycosides (optional)
PLUS
Vancomycin
Vancomycin, linezolid or daptomycin	Suspected catheter-related infections
	Skin or soft-tissue infection
	Risk of methicillin-resistant Staphylococcus aureus
Linezolid or daptomycin	Risk of vancomycin-resistant Enterococcus spp.
Carbapenem	Risk of extended-spectrum β-lactamase-producing gram negative bacteria
Polymyxin-colistin or tigecycline	Risk of Klebsiella pneumonia carbapenemase
Ciprofloxacin + clindamycin	Penicillin-allergic patients
OR
Aztreonam + vancomycin
Trimethoprim/sulfamethoxazole	Suspected Pneumocystis pneumonia
Antifungal drugs (echinocandins, amphotericin B lipid-based formulations)	Suspected invasive mycosis

Citation: Martos-Benítez FD, Soler-Morejón CD, Lara-Ponce KX, Orama-Requejo V, Burgos-Aragüez D, Larrondo-Muguercia H, Lespoir RW. Critically ill patients with cancer: A clinical perspective. World J Clin Oncol 2020; 11(10): 809-835
URL: https://www.wjgnet.com/2218-4333/full/v11/i10/809.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i10.809